SCHEMBL3943293

SCHEMBL3943293

CN(C)Cc1ccc(NC(=C2C(=O)Nc3ccccc32)c2ccc3c(c2)ncn3C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 4/20 0.42
NPC1 O15118 11/20 0.39
RAB9A P51151 11/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
TP53 P04637 3/20 0.39
NAMPT P43490 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
GFER P55789 2/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NOTUM Q6P988 2/20 0.37
KDM4E B2RXH2 3/20 0.36
GAA P10253 3/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943289 1.00 SLC2A1 (0.42) SLC2A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL3934655 0.89 NPC1 (0.44) SLC2A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL3942226 0.89 NPC1 (0.44) SLC2A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL3933903 0.86 RAB9A (0.46) SLC2A1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3933909 0.86 RAB9A (0.46) SLC2A1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3943285 0.84 NPC1 (0.43) NPC1RAB9ASMN1; SMN2TP53NAMPT
SCHEMBL8012579 0.83 NPC1 (0.49) NPC1RAB9ASMN1; SMN2TP53NAMPT
SCHEMBL8012581 0.83 NPC1 (0.49) NPC1RAB9ASMN1; SMN2TP53NAMPT
SCHEMBL3933394 0.83 SLC2A1 (0.40) SLC2A1NPC1RAB9ASMN1; SMN2NAMPT
SCHEMBL3933400 0.81 RAB9A (0.45) SLC2A1NPC1RAB9ASMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 SLC2A1 2424/4885NPC1 4723/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.